Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide in relapsed and refractory multiple myeloma
NCT03374085Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Feb 2018
- Primary completion
- Aug 2025
- Countries
- 11
01
Overview
A Phase 2 trial of mezigdomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Feb 2018; status: terminated.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03374085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374085.